Contact Us
Drug Search Results
More Filters [+]

Seltorexant

Alternative Names: seltorexant, jnj-42847922, jnj-922, jnj 42847922, jnj42847922, min-202, min202
Latest Update: 2025-03-04
Latest Update Note: Clinical Trial Update

Product Description

Johnson & Johnson is developing Seltorexant as a treatment for major depressive disorder with insomnia symptoms. (Sourced from: https://www.investor.jnj.com/pipeline/development-pipeline/default.aspx)

Mechanisms of Action: OX2R Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Seltorexant

Countries in Clinic: Argentina, Belgium, Brazil, Bulgaria, Canada, Colombia, Czech Republic, Germany, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Poland, Portugal, Russia, Serbia, Slovakia, South Africa, Spain, Sweden, Taiwan, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 14

Highest Development Phases

Phase 3: Depressive Disorder, Major|Insomnia

Phase 2: Alzheimer Disease

Phase 1: Healthy Volunteers|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
42847922MDD3003

P3

Recruiting

Depressive Disorder, Major

2026-12-30

42847922MDD3003

P3

Unknown Status

Depressive Disorder, Major|Insomnia

2026-12-30

CR109177

P2

Completed

Alzheimer Disease

2023-11-10

CR108810

P3

Completed

Depressive Disorder, Major

2023-10-03

Recent News Events

Date

Type

Title

10/24/2024

News Article

 Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress

07/17/2024

News Article

 Johnson & Johnson reports Q2 2024 results

06/01/2024

PubMed

 Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.

05/29/2024

News Article

 Johnson & Johnson pivotal study of seltorexant shows statistically significant and clinically meaningful improvement in depressive symptoms and sleep disturbance outcomes

04/01/2024

PubMed

 Heterogeneity of outcome measures in depression trials and the relevance of the content of outcome measures to patients: a systematic review.

02/08/2024

News Article

 Major Depressive Disorder - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033 - Thelansis Knowledge Partners

06/19/2023

PubMed

 Orexin Receptor Antagonists as Adjunct Drugs for the Treatment of Depression: A Mini Meta-Analysis.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions